Interpace Biosciences, Inc. (IDXG)
Tests thyroid nodules to determine if they're cancerous using genetic analysis.
$1.55+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+86.7%
The outlook
IDXG is trading near the middle of its 52-week range with mixed momentum relative to its moving averages. Analyst coverage appears thin, and the stock's neutral StockGlow score reflects balanced sentiment without a clear directional lean. The low trailing P/E of 1.8 suggests modest valuation, though this warrants context on profitability.
What’s behind the score
Price trendMixed vs its moving averages
52-week range48% of the way from its 52-week low to high
Market cap
$42.9M
52-wk high
$2.40
52-wk low
$0.77
50-day avg
$1.66
200-day avg
$1.54
Trailing P/E
1.8